Dyskinesia and brain-derived neurotrophic factor levels after long-term levodopa and nicotinic receptor agonist treatments in female mice with near-total unilateral dopaminergic denervation

Show full item record



Permalink

http://hdl.handle.net/10138/269348

Citation

BMC Neuroscience. 2018 Nov 29;19(1):77

Title: Dyskinesia and brain-derived neurotrophic factor levels after long-term levodopa and nicotinic receptor agonist treatments in female mice with near-total unilateral dopaminergic denervation
Author: Leino, Sakari; Kohtala, Samuel; Rantamäki, Tomi; Koski, Sini K; Rannanpää, Saara; Salminen, Outi
Publisher: BioMed Central
Date: 2018-11-29
URI: http://hdl.handle.net/10138/269348
Abstract: Abstract Background The treatment of Parkinson’s disease is often complicated by levodopa-induced dyskinesia (LID). Nicotinic acetylcholine receptor agonists can alleviate LID in animal models but may be less effective in conditions of severe dopaminergic denervation. While the mechanisms of LID remain incompletely understood, elevated corticostriatal levels of the brain-derived neurotrophic factor (BDNF) have been suggested to play a role. Here, female mice with near-total unilateral 6-hydroxydopamine-induced nigrostriatal lesions were chronically treated with levodopa, and the effects of the α7 nicotinic receptor partial agonist AZD0328 and nicotine on LID were assessed. At the end of the experiment, BDNF protein levels in the prefrontal cortex and striatum were measured. Results Five-day treatments with three escalating doses of AZD0328 and a 10-week treatment with nicotine failed to alleviate LID. BDNF levels in the lesioned striatum correlated positively with LID severity, but no evidence was found for a levodopa-induced elevation of corticostriatal BDNF in the lesioned hemisphere. The nicotine treatment decreased BDNF levels in the prefrontal cortex but had no effect on striatal BDNF. Conclusions The findings suggest that treatment of LID with nicotinic agonists may lose its effectiveness as the disease progresses, represent further evidence for a role for BDNF in LID, and expand previous knowledge on the effects of long-term nicotine treatment on BDNF.
Subject: Parkinson’s disease
Levodopa-induced dyskinesia
BDNF
Nicotine
Alpha7 nicotinic receptors


Files in this item

Total number of downloads: Loading...

Files Size Format View
12868_2018_Article_478.pdf 1.119Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record